Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,136 | $457.79 | $520,054.78 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $457.19 to $458.18, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 527 | $456.41 | $240,526.91 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,036 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $456.16 to $456.65, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,773 | $455.57 | $807,717.28 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,563 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $455.00 to $455.98, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 662 | $454.15 | $300,647.10 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $453.76 to $454.74, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 788 | $453.21 | $357,125.78 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,998 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $452.69 to $453.68, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 751 | $451.95 | $339,415.88 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,786 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.59 to $452.57, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 600 | $451.07 | $270,639.90 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,537 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.48 to $451.44, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:36 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 326 | $450.37 | $146,820.62 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 6 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,406 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.37 to $450.625, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 20:36 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 2,583 | $449.09 | $1,159,999.47 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,732 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.63, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 109 | $452.13 | $49,282.17 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,315 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 1,050 | $451.54 | $474,117.00 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,424 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.02 to $452.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 1,698 | $450.39 | $764,762.22 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,474 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.075 to $450.95, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:36 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 6,732 | $449.35 | $3,025,024.20 |
DisclosureSEC source: 0000914190-21-000187 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,172 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 349 | $450.10 | $157,084.90 |
DisclosureSEC source: 0000914190-21-000185 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,904 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 23:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
SaleCommon Stock | 7,132 | $449.10 | $3,202,981.20 |
DisclosureSEC source: 0000914190-21-000185 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,253 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.97, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 20:59 UTC |
Kelderman KimPres. Diagnostics & Genom
|
SaleCommon Stock | 811 | $433.00 | $351,163.00 |
DisclosureSEC source: 0000914190-21-000183 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 9,942 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · derivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 9,942 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully exercisable. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 310 | $424.59 | $131,623.40 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $424.38 to $424.785, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,700 | $423.74 | $720,356.64 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,447 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $423.346 to $424.22, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 2,000 | $422.81 | $845,628.20 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,147 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $422.345 to $423.30, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 2,396 | $421.93 | $1,010,934.70 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,147 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $421.29 to $422.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 2,029 | $420.66 | $853,523.20 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,543 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $420.29 to $421.23, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,507 | $419.88 | $632,765.04 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,572 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $419.29 to $420.28, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 07, 2021 Filed Jun 9, 2021 20:48 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 9,942 | $106.59 | $1,059,717.78 |
DisclosureSEC source: 0000914190-21-000181 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:26 UTC |
Kelderman KimPres. Diagnostics & Genom
|
SaleCommon Stock | 845 | $424.00 | $358,280.00 |
DisclosureSEC source: 0000914190-21-000166 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 811 Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:25 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 36,849 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000165 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,849 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:25 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 21,305 | $420.12 | $8,950,656.60 |
DisclosureSEC source: 0000914190-21-000165 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,385 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:25 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 36,849 | $94.35 | $3,476,703.15 |
DisclosureSEC source: 0000914190-21-000165 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:54 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000134 · edgar.xml · derivative · entry 3 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 1,667 restricted stock units vest on 5/1/2021. F2 · derivative.expiration_date: 1,667 restricted stock units vest on 5/1/2021. Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:54 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Tax withholdingCommon Stock | 856 | $427.49 | $365,931.44 |
DisclosureSEC source: 0000914190-21-000134 · edgar.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,656 Read SEC document |
| May 01, 2021 Filed May 4, 2021 20:54 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 1,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000914190-21-000134 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:28 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 10,997 | $0.00 Strike: $372.44 | $0.00 |
DisclosureSEC source: 0000914190-21-000072 · edgar.xml · derivative · entry 17 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,997 Underlying: Common Stock · 10,997 shares Expires 2028-03-01 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:38 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $94.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000067 · edgar.xml · derivative · entry 5 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,849 Underlying: Common Stock · 30,000 shares Expires 2021-08-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:38 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 17,428 | $411.00 | $7,162,908.00 |
DisclosureSEC source: 0000914190-21-000067 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,841 F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:38 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 30,000 | $94.35 | $2,830,500.00 |
DisclosureSEC source: 0000914190-21-000067 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:46 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000050 · edgar.xml · derivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,942 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:46 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 600 | $401.52 | $240,910.50 |
DisclosureSEC source: 0000914190-21-000050 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $401.40 to $401.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:46 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 9,400 | $400.32 | $3,762,997.66 |
DisclosureSEC source: 0000914190-21-000050 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,737 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $400.035 to $400.88, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:46 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000050 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · derivative · entry 5 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,538 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully exercisable. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 3,326 | $399.12 | $1,327,461.48 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · nonDerivative · entry 3 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,124 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $399.00 to $399.465, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC |
Furlow Brenda S.SVP - General Counsel
|
SaleCommon Stock | 6,674 | $398.40 | $2,658,890.90 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,450 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $398.00 to $398.995, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:42 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000048 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,124 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $66.90 | $0.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · derivative · entry 5 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC |
Nusse RoelandDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $70.35 | $0.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · derivative · entry 4 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 1,000 shares Expires 2021-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC |
Nusse RoelandDirector
|
SaleCommon Stock | 6,000 | $385.08 | $2,310,481.20 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · nonDerivative · entry 3 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,765 Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 5,000 | $66.90 | $334,500.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · nonDerivative · entry 2 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:26 UTC |
Nusse RoelandDirector
|
Exercise / conversionCommon Stock | 1,000 | $70.35 | $70,350.00 |
DisclosureSEC source: 0000914190-21-000041 · edgar.xml · nonDerivative · entry 1 Nusse Roeland · CIK 0001492695 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2021 Filed Feb 9, 2021 23:31 UTC |
Kelderman KimPres. Diagnostics & Genom
|
SaleCommon Stock | 823 | $388.45 | $319,694.35 |
DisclosureSEC source: 0000914190-21-000039 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 845 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.